LeadIQ logo
Learn more at LeadIQ.com

Insights

Expanding Vaccine Portfolio BioNTech is actively developing multiple mRNA vaccine candidates for a variety of infectious diseases, presenting potential sales opportunities for public health emergencies and global health initiatives.

Unique Immunotherapy Offerings With a diverse pipeline including mRNA-based therapies, CAR T cells, protein-based therapeutics, and small molecules, BioNTech offers a unique range of immunotherapy solutions that could attract partnerships or licensing deals.

Legal Support Services BioNTech recently appointed a Chief Legal Officer and a new Chief Commercial Officer, indicating a need for legal and commercial support services that could be explored as sales prospects for law firms and consulting companies.

Competitive Partnerships Despite patent issues and legal disputes, BioNTech's collaborations with other companies in vaccine development create opportunities for strategic partnerships, joint ventures, or technology licensing agreements.

Business Expansion Initiatives BioNTech's expansion of manufacturing capacity for mRNA vaccines signals potential opportunities for equipment suppliers, logistics providers, and service vendors looking to partner with a leading biotech company.

BioNTech SE Tech Stack

BioNTech SE uses 8 technology products and services including QlikView, Zendesk, IBM Watson, and more. Explore BioNTech SE's tech stack below.

  • QlikView
    Business Intelligence
  • Zendesk
    Documentation Tools
  • IBM Watson
    IT Infrastructure
  • UNIX
    Operating Systems
  • Pantheon
    Platform As A Service
  • Yoast SEO
    Search Engines
  • Base SAS
    Software As A Service
  • Twitter
    Widgets

Media & News

BioNTech SE's Email Address Formats

BioNTech SE uses at least 1 format(s):
BioNTech SE Email FormatsExamplePercentage
First.Last@biontech.deJohn.Doe@biontech.de
93%
FLast@biontech.deJDoe@biontech.de
4%
First.Middle@biontech.deJohn.Michael@biontech.de
2%
LF@biontech.deDJ@biontech.de
1%

Frequently Asked Questions

Where is BioNTech SE's headquarters located?

Minus sign iconPlus sign iconBioNTech SE's main headquarters is located at An der Goldgrube 12 Mainz, Rhineland-Palatinate 55131 DE. The company has employees across 6 continents, including EuropeNorth AmericaAsia.

What is BioNTech SE's phone number?

Minus sign iconPlus sign icon You can contact BioNTech SE's main corporate office by phone at
+49-6131-9****
. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is BioNTech SE's stock symbol?

Minus sign iconPlus sign iconBioNTech SE is a publicly traded company; the company's stock symbol is BNTX.

What is BioNTech SE's official website and social media links?

Minus sign iconPlus sign iconBioNTech SE's official website is biontech.de and has social profiles on LinkedIn.

How much revenue does BioNTech SE generate?

Minus sign iconPlus sign icon As of January 2025, BioNTech SE's annual revenue reached $18B.

What is BioNTech SE's SIC code NAICS code?

Minus sign iconPlus sign iconBioNTech SE's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does BioNTech SE have currently?

Minus sign iconPlus sign iconAs of January 2025, BioNTech SE has approximately 4.9K employees across 6 continents, including EuropeNorth AmericaAsia. Key team members include Chief Executive Officer & Co-Founder: U. S.Chief Operating Officer: S. P.Chief Financial Officer: J. H.. Explore BioNTech SE's employee directory with LeadIQ.

What industry does BioNTech SE belong to?

Minus sign iconPlus sign iconBioNTech SE operates in the Biotechnology Research industry.

What technology does BioNTech SE use?

Minus sign iconPlus sign iconBioNTech SE's tech stack includes QlikViewZendeskIBM WatsonUNIXPantheonYoast SEOBase SASTwitter.

What is BioNTech SE's email format?

Minus sign iconPlus sign iconBioNTech SE's email format typically follows the pattern of . Find more BioNTech SE email formats with LeadIQ.

How much funding has BioNTech SE raised to date?

Minus sign iconPlus sign icon As of January 2025, BioNTech SE has raised $145M in funding. The last funding round occurred on May 29, 2024 for $145M.

When was BioNTech SE founded?

Minus sign iconPlus sign iconBioNTech SE was founded in 2008.
BioNTech SE

BioNTech SE

Biotechnology ResearchRhineland-Palatinate, Germany1001-5000 Employees

BioNTech is a global next generation immunotherapy company aspiring to translate science into survival. Around 6.100 pioneers currently work with us, employing a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Our broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor (CAR) T cells, several protein-based therapeutics, including bispecific immune checkpoint modulators, targeted cancer antibodies and antibody-drug conjugate (ADC) therapeutics, as well as small molecules. 
  
Based on our deep expertise in mRNA vaccine development and in-house manufacturing capabilities, we are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. 

To learn more about us, please visit www.BioNTech.com. 

Our privacy statement can be found here:  https://www.biontech.com/int/en/home/data-privacy-statement.html 

Our imprint can be found:
https://www.biontech.com/int/en/home/imprint.html

Section iconCompany Overview

Headquarters
An der Goldgrube 12 Mainz, Rhineland-Palatinate 55131 DE
Phone number
+49-6131-9****
Website
biontech.de
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
BNTX
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2008
Employees
1001-5000

Section iconMedia & News

Section iconFunding & Financials

  • $145M

    BioNTech SE has raised a total of $145M of funding over 10 rounds. Their latest funding round was raised on May 29, 2024 in the amount of $145M.

  • $1B

    BioNTech SE's revenue is in the range of $1B

Section iconFunding & Financials

  • $145M

    BioNTech SE has raised a total of $145M of funding over 10 rounds. Their latest funding round was raised on May 29, 2024 in the amount of $145M.

  • $1B

    BioNTech SE's revenue is in the range of $1B

Company Leadership

  • Stylized image of a person
    U. S.
    Chief Executive Officer & Co-Founder
    Phone icon
    Mobile Phone
  • Stylized image of a person
    S. P.
    Chief Operating Officer
    Phone icon
    Mobile Phone
  • Stylized image of a person
    J. H.
    Chief Financial Officer
    Phone icon
    Mobile Phone
  • Stylized image of a person
    J. R.
    Chief Legal Officer And Chief Business Officer
    Phone icon
    Mobile Phone
  • Stylized image of a person
    A. H.
    Chief Commercial Officer (cco)
    Phone icon
    Mobile Phone

Employee Directory

  • Stylized image of a person
    M. L.
    Global Prozesses Owner Plan 2 Produce
    Phone icon
    Mobile Phone
  • Stylized image of a person
    A. H.
    Chief Commercial Officer (cco)
    Phone icon
    Mobile Phone
  • Stylized image of a person
    C. S.
    System Owner
    Phone icon
    Mobile Phone
  • Stylized image of a person
    C. H.
    Cofounder And Deputy Chairman Supervisory Board
    Phone icon
    Mobile Phone
  • Stylized image of a person
    E. H.
    Chief Of Staff To Ceo & Cmo
    Phone icon
    Mobile Phone

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.